Gout (Chronic Refractory) Market Assessment 2024 Featuring 15 Companies and 20 Key Drugs - Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access [Yahoo! Fi...
Cartesian Therapeutics, Inc. (RNAC)
Company Research
Source: Yahoo! Finance
This report provides comprehensive insights into several key aspects of disease management and treatment strategies. It begins with a disease overview, offering a detailed review of the pathophysiology and highlighting potential druggable targets that could be crucial for therapeutic interventions. The epidemiology section delves into the prevalence of the disease, along with an analysis of the diagnosed and drug-treated population across various key market segments. This is followed by a breakdown of the current treatment options, including the treatment decision tree, as well as the strengths and weaknesses of both on-label and off-label treatments currently in use. The report also highlights unmet needs, identifying areas where treatment gaps exist, presenting opportunities to improve disease management. The pipeline analysis compares both current and emerging therapies, assessing them on the basis of efficacy, safety, and delivery metrics, while evaluating their potential to
Show less
Read more
Impact Snapshot
Event Time:
RNAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAC alerts
High impacting Cartesian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAC
News
- Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last? [Yahoo! Finance]Yahoo! Finance
- Cartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswire
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.MarketBeat
- Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile DermatomyositisGlobeNewswire
- Cartesian Therapeutics Announces New Employment Inducement Grant [Yahoo! Finance]Yahoo! Finance
RNAC
Earnings
- 5/8/24 - Miss
RNAC
Sec Filings
- 10/4/24 - Form SC
- 10/4/24 - Form 4
- 10/2/24 - Form EFFECT
- RNAC's page on the SEC website